Physician profile
Sonia Devgan
NPI 1528002839
$4,596.27
in general payments reported to CMS, 2019-2025
28 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2021: $573 · 2022: $539 · 2023: $821 · 2024: $663 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,005.92 | 2019-2025 | Evenity, Otezla |
| Abbott Laboratories | $347.06 | 2023-2024 | Xact, Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $282.62 | 2019-2022 | |
| Novo Nordisk INC | $237.96 | 2024-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $231.40 | 2019 | |
| Intuitive Surgical, INC. | $229.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $225.91 | 2024-2025 | Airsupra |
| Amarin Pharma, INC. | $128.35 | 2019 | |
| Depuy Synthes Sales INC. | $125.00 | 2019 | |
| Abbvie INC. | $125.00 | 2023 | Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2022 | |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Therapeuticsmd, INC. | $124.58 | 2019 | |
| Boston Scientific Corporation | $122.20 | 2025 | Farapulse |
| Eisai INC. | $119.70 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $119.18 | 2025 | Symbravo |
| Biohaven Pharmaceuticals, INC. | $118.59 | 2021 | |
| Spr Therapeutics, INC | $117.83 | 2023 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $115.33 | 2025 | |
| Sanofi Pasteur INC. | $110.42 | 2023 | |
| Stryker Corporation | $105.13 | 2024 | Audion Et Dilation System |
| Vertiflex, INC. | $84.18 | 2019 | |
| Tris Pharma INC | $80.09 | 2023 | Quillichew Er, Dyanavel Xr, Quillivant |
| Gilead Sciences, INC. | $70.04 | 2023 | Epclusa |
| Hologic Sales and Service, LLC | $45.41 | 2023 | Aptima, Thinprep 2000 Processor |
| Djo, LLC | $28.25 | 2025 | |
| Pfizer INC. | $23.40 | 2024 | |
| Genentech USA, INC. | $23.29 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Devgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.